PMVP Jan 2025 2.500 call
| Previous close | 0.8100 |
| Open | 0.8100 |
| Bid | 0.0000 |
| Ask | 2.0000 |
| Strike | 2.50 |
| Expiry date | 2025-01-17 |
| Day's range | 0.8100 - 0.8100 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.18k |
GlobeNewswirePMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June
PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences in June. Management will also participate in one-on-one investor meetings. Jefferies
- GlobeNewswire
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma’s rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation. Across all human cancers, TP5
ZacksHere's Why You Should Buy Acrivon Therapeutics (ACRV) Stock
Here, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move.
